Evaluation of the Safety and Effectiveness of the OPTIMIZER System in Subjects With Heart Failure: FIX-HF-5
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00112125|
Recruitment Status : Active, not recruiting
First Posted : May 30, 2005
Last Update Posted : February 27, 2019
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure, Congestive||Device: OPTIMIZER System||Phase 2 Phase 3|
IMPULSE Dynamics' FIX HF 5 US Study is a prospective, multi-center, study to evaluate the safety and efficacy of cardiac contractility modulation (CCM) signals delivered by the implantable OPTIMIZER™ System in patients with NYHA class III/IV heart failure. The study will involve the recruitment of approximately 420 subjects at a total of up to 50 sites nationwide.
Those subjects who fulfill all inclusion and exclusion criteria based upon baseline test results will be randomized to receive the OPTIMIZER™ System or to a control group. All subjects randomized will be followed for 1 year and shall receive the same study related assessments throughout the course of the study. In addition, all subjects will continue to receive optimal medical therapy for the treatment of their heart failure.
The primary efficacy assessment consists of a change in exercise tolerance measured by cardiopulmonary exercise testing at baseline and 6 months. Safety variables, such as the rate and cause of hospitalizations or death, shall be collected in both groups and shall be compared at 12 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||428 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of the Safety and Efficacy of the OPTIMIZER System With Active Fixation Leads in Subjects With Heart Failure Resulting From Systolic Dysfunction: FIX-HF-5|
|Study Start Date :||February 2005|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||April 2019|
Experimental: Optimizer System + Optimal medical treatment
Optimizer System implanted and cardiac contractility modulation therapy activated.
Device: OPTIMIZER System
|No Intervention: Optimal medical treatment|
- Change in exercise tolerance quantified by change in ventilatory threshold measured on cardiopulmonary exercise test [ Time Frame: 6 months ]
- Efficacy: Improvement in New York Heart Association (NYHA) Class; improvement in quality of life; change in left ventricular ejection fraction; change in left ventricular end diastolic dimension. [ Time Frame: 6 months ]
- Safety: all-cause mortality; cardiac mortality; the rate of all-cause hospitalizations; the rate of cardiac-related hospitalizations; overall incidence and severity of adverse events [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00112125
|United States, New York|
|Orangeburg, New York, United States, 10962|
|Study Director:||Dan Burkhoff, M.D, Ph.D.||Impulse Dynamics|